Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Fund Type: SICAV
  • Objective: Health Care Sector
  • Asset Class: Equity
  • Geographic Focus: International

Credit Suisse Lux Biotechnology Equity Fund

+ Add to Watchlist

CLABI1B:LX

506.56 USD 4.92 0.98%

As of 00:59:30 ET on 03/02/2015.

Snapshot for Credit Suisse Lux Biotechnology Equity Fund (CLABI1B)

Year To Date: +13.18% 3-Month: +12.87% 3-Year: +42.80% 52-Week Range: 312.45 - 506.69
1-Month: +6.53% 1-Year: +29.12% 5-Year: +29.76% Beta vs NBI: 1.04

Mutual Fund Chart for CLABI1B

No chart data available.
  • CLABI1B:LX 506.56
  • 1M
  • 1Y
Interactive CLABI1B Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Fund Profile & Information for CLABI1B

Credit Suisse Lux Biotechnology Equity Fund is a SICAV incorporated in Luxembourg. The Fund is actively managed aiming to outperform the return of the NASDAQ Biotechnology TR benchmark. The Fund mainly invests in equity and equity-type securities of issuers engaged in the biotechnology industry.

Inception Date: 10-05-2001 Telephone: -
Managers: IRENE BEATRICE PUETTNER
Web Site: www.credit-suisse.com

Fundamentals for CLABI1B

NAV (on 2015-03-02) 506.56
Assets (M) (on 2015-03-02) 251.64
Fund Leveraged N
Minimum Investment 1,000,000.00
Minimum Subsequent Investment 250,000.00

Dividends for CLABI1B

No dividends reported

Fees & Expenses for CLABI1B

Front Load 0.00
Back Load 0.00
Current Mgmt Fee 1.20
Redemption Fee 0.00
12b1 Fee -
Expense Ratio -

Top Fund Holdings for CLABI1B

Filing Date: 12/31/2014
Name Position Value % of Total
Amgen Inc 105,973 16,880,439 7.501%
Celgene Corp 150,276 16,809,873 7.470%
Gilead Sciences Inc 162,484 15,315,742 6.806%
Biogen Idec Inc 44,745 15,188,690 6.749%
Regeneron Pharmaceuticals Inc 27,000 11,076,750 4.922%
Vertex Pharmaceuticals Inc 90,000 10,692,000 4.751%
Incyte Corp 145,000 10,600,950 4.711%
BioMarin Pharmaceutical Inc 115,444 10,436,138 4.637%
Alexion Pharmaceuticals Inc 52,752 9,760,703 4.337%
Medivation Inc 80,000 7,968,800 3.541%

Quotes delayed, except where indicated otherwise. Mutual fund NAVs include dividends. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil